{"id":"W4379281880","doi":"10.1200/jco.2023.41.16_suppl.tps7586","title":"SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Oncology; Gemcitabine; Phases of clinical research; Antibody-drug conjugate; Diffuse large B-cell lymphoma; Oxaliplatin; Refractory (planetary science); Lymphoma; Gastroenterology; Clinical trial; Chemotherapy; Cancer; Antibody; Immunology; Monoclonal antibody; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009232074,0.001027575,0.001497488,0.0003132967,0.0002848262,0.0009762946,0.0007303708,0.0009998598,0.005024224],"category_scores_gemma":[0.0006158315,0.0004641748,0.001445743,0.0003047463,0.0006324439,0.0006856615,0.0003400878,0.002677484,0.0009123342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009974426,"about_ca_system_score_gemma":0.0009820056,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009986968,"about_ca_topic_score_gemma":0.003319483,"domain_scores_codex":[0.9997681,0.00009850698,0.00001048841,0.00004572873,0.00002312911,0.00005412335],"domain_scores_gemma":[0.9996507,0.00005572134,0.00006654632,0.00002190619,0.00001549446,0.0001896383],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8431776,0.01970548,0.003765671,0.001478176,0.002009046,0.0001798113,0.0002657553,0.001777806,0.02140727,0.0004067525,0.004183674,0.101643],"study_design_scores_gemma":[0.7460021,0.2366385,0.009757944,0.00009131528,0.0007784691,0.0002454203,0.00006765634,0.001323519,0.001472612,0.0003052672,0.003288161,0.00002906222],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895391,0.003961349,0.0003235378,0.0007025978,0.000259049,0.001513278,0.001261246,0.0001176955,0.002322145],"genre_scores_gemma":[0.9884397,0.002712036,0.0010351,0.001078864,0.0001932522,0.001757646,0.001957269,0.00002474091,0.002801453],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005024224,"threshold_uncertainty_score":0.01680773,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0704012691811073,"score_gpt":0.4466151810505222,"score_spread":0.3762139118694149,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}